CFO Peter Bühler reported that product sales reached €163.3 million, with IXIARO contributing €94.1 million and DUKORAL €32.3 million. Initial IXCHIQ sales were reported at €3.7 million ...

It currently provides three proprietary travel vaccines: IXIARO, DUKORAL, and IXCHIQ. The IXIARO is an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active ...